Progression‐free survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · high‐grade glioma
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · women with stage IIIc or IV ovarian cancer
It is very uncertain whether ultra‐radical (extensive) surgery changes progression‐free survival compared with standard surgery (very low certainty).
1 finding from 1 review
Progression‐free survival · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel showed no clear difference in progression‐free survival compared with 250 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Progression‐free survival · women with recurrent epithelial ovarian cancer
135 mg/m2 paclitaxel showed no clear difference in progression‐free survival compared with 175 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Progression‐free survival · women with recurrent epithelial ovarian cancer
It is very uncertain whether weekly paclitaxel changes progression‐free survival compared with three‐weekly paclitaxel (very low certainty).
1 finding from 1 review
Progression‐free survival · children with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · women with advanced EOC after primary IDS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival
Hormone replacement therapy (HRT) showed no clear difference in progression‐free survival compared with no HRT (low certainty).
1 finding from 1 review
Progression‐free survival · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) changes progression‐free survival compared with observation alone (very low certainty).
1 finding from 1 review
Progression‐free survival · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes progression‐free survival compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Progression‐free survival · people with single or solitary brain metastasis
Surgery plus whole brain radiotherapy (WBRT) showed no clear difference in progression‐free survival compared with stereotactic radiosurgery plus WBRT (low certainty).
1 finding from 1 review
Progression‐free survival
It is very uncertain whether extended‐field chemoradiotherapy changes progression‐free survival compared with pelvic chemoradiotherapy (very low certainty).
1 finding from 1 review
Progression‐free survival
Extended‐field radiotherapy showed no clear difference in progression‐free survival compared with pelvic radiotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival
Extended‐field radiotherapy probably leads to lower progression‐free survival compared with pelvic chemoradiotherapy (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma
The intervention showed no clear difference in progression‐free survival (high certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to lower progression‐free survival (high certainty).
1 finding from 1 review
Progression‐free survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy may leads to higher progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review